Eden Research posts interim loss but outlines expansion plans

Eden Research, a UK-based developer of plant-derived biopesticides, reported a slowdown in first-half revenue but highlighted new market approvals and partnerships that it says will support growth in the coming year.

The AIM-quoted company posted revenue of £1.2 million ($1.6 million) for the six months ended June 30, down 37% from the same period in 2024, reflecting seasonal factors and reduced demand for its flagship fungicide Mevalone during unusually hot and dry conditions in southern Europe. The operating loss widened to £1.7 million ($2.3 million). Eden’s cash balance fell to £1.8 million ($2.4 million) from £4.9 million ($6.6 million) a year earlier, though management said it does not expect to raise additional funds for working capital in the near term.

Despite the weaker interim results, the company pointed to regulatory and commercial advances that expand its global reach. Mevalone gained approval in California to control powdery mildew on grapes, opening access to the largest US wine-growing region. In Kenya, Eden appointed Andermatt Kenya as exclusive distributor, with initial orders expected before the fiscal year end. The firm also struck a supply agreement with France’s Véto-pharma to provide thymol for bee health products in the US.

Eden is seeking to build scale as regulators phase out conventional chemistries in favor of sustainable alternatives. In the EU, competing products to Mevalone and Cedroz have been withdrawn, creating opportunities for Eden to capture market share. The company is also developing Ecovelex, a bird-repellent seed treatment for maize, in partnership with Corteva Agriscience. Temporary approval in Italy has supported sales, while full EU authorization is expected in 2026.

Beyond its established products, Eden is advancing two next-generation candidates: a fungicide targeting late blight in potatoes—a market worth about €200 million ($213 million) annually in Europe—and a second insecticide aimed at lepidoptera pests. Both address segments where conventional tools are being restricted.

The company reiterated guidance of £5 million ($6.8 million) in revenue, now spread over a 15-month reporting period ending March 2026, following a decision to shift its year-end to align with agricultural seasonality. Chief Executive Sean Smith said Eden is positioned to benefit from “the ever-growing industry transition from conventional chemistry to natural, sustainable chemistry.”

The global biopesticides market is projected to more than double to $15.7 billion by 2029, according to industry data cited by Eden. With regulatory drivers accelerating adoption and multinational partners such as Corteva, Sipcam Oxon, and Eastman Chemical involved in commercialization, Eden’s trajectory is closely watched by investors and industry participants seeking signals on how quickly biological crop protection can replace conventional pesticides.